12:26 PM EST - BriaCell Therapeutics Corp : Announces that it has secured an exclusive license from University of Maryland, Baltimore County to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer. In animal models, sCD80 was well-tolerated and stopped tumor growth by potentially restoring natural anti-tumor immunity. Additionally, strong anti-tumor activity of sCD80 has been reported in multiple tumor types. BriaCell Therapeutics Corp
shares T.BCT are trading up $0.06 at $8.53.
